Characterization of Thymoquinone-Sulfobutylether-β-Cyclodextrin Inclusion Complex for Anticancer Applications

Thymoquinone (TQ) is a quinone derived from the black seed Nigella sativa and has been extensively studied in pharmaceutical and nutraceutical research due to its therapeutic potential and pharmacological properties. Although the chemopreventive and potential anticancer effects of TQ have been reported, its limited solubility and poor delivery remain the major limitations. In this study, we aimed to characterize the inclusion complexes of TQ with Sulfobutylether-beta-cyclodextrin (SBE beta-CD) at four different temperatures (293-318 K). Additionally, we compared the antiproliferative activity of TQ alone to TQ complexed with SBE-beta-CD on six different cancer cell lines, including colon, breast, and liver cancer cells (HCT-116, HT-29, MDA-MB-231, MCF-7, SK-BR-3, and HepG2), using an MTT assay. We calculated the thermodynamic parameters (Delta H, Delta S, and Delta G) using the van't Holf equation. The inclusion complexes were characterized by X-ray diffraction (XRD), Fourier transforms infrared (FT-IR), and molecular dynamics using the PM6 model. Our findings revealed that the solubility of TQ was improved by >= 60 folds, allowing TQ to penetrate completely into the cavity of SBE-beta-CD. The IC50 values of TQ/SBE- beta-CD ranged from 0.1 +/- 0.01 mu g/mL against SKBR-3 human breast cancer cells to 1.2 +/- 0.16 mu g/mL against HCT-116 human colorectal cancer cells, depending on the cell line. In comparison, the IC50 values of TQ alone ranged from 0.2 +/- 0.01 mu g/mL to 4.7 +/- 0.21 mu g/mL. Overall, our results suggest that SBE-beta-CD can enhance the anticancer effect of TQ by increasing its solubility and bioavailability and cellular uptake. However, further studies are necessary to fully understand the underlying mechanisms and potential side effects of using SBE-beta-CD as a drug delivery system for TQ.

Automated summary

This study aimed to improve the solubility of TQ by forming inclusion complexes with SBE-beta-CD and found that these complexes exhibited enhanced antiproliferative activity against various cancer cell lines. However, further research is needed to fully understand the mechanisms and potential side effects of using SBE-beta-CD as a drug delivery system for TQ.